Metformin can Activate Imidazoline I-2 Receptors to Lower Plasma Glucose in Type 1-like Diabetic Rats

Abstract

Metformin is widely used in clinic for handling the diabetic disorders. However, action mechanisms of metformin remain obscure. It has recently been indicated that guanidinium derivatives are ligands to activate type-2 imidazoline receptors (I-2 receptors) that can improve diabetes through increment in skeletal muscle glucose uptake. Also, activation of I-2 receptors can increase the release of ß-endorphin in diabetic animals. Because metformin is a guanidinium derivative, we were interested in the effect of metformin on I-2 receptors. In the present study, the marked blood glucose-lowering action of metformin in streptozotocin-induced type-1 like diabetes rats was blocked by specific I-2 receptor antagonist, BU224, in a dose-dependent manner. Also, the increase of ß-endorphin release by metformin was blocked by BU224 in same manner. A specific competition between metformin and BU224 was observed in isolated adrenal medulla. Otherwise, amiloride at the dose sufficient to block I-2A receptor abolished the metformin-induced ß-endorphin release, but only the blood glucose-lowering action of metformin was markedly reduced. In addition, the blood glucose-lowering action of metformin in bilateral adrenalectomized rats was diminished by amiloride at higher doses. These results suggest that metformin might activate imidazoline I-2 receptors while I-2A receptors link the increase of ß-endorphin release and I-2B receptors couple to the other actions for lowering of blood glucose in type-1 like diabetic rats.

amiloride - β-endorphin - diabetes - imidazoline receptor - metformin

References

• 1 Bailey CJ, Turner RC. Metformin.  N Engl J Med. 1996;  334 574-579
• 2 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association; European Association for the Study of Diabetes . Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetologia. 2009;  52 17-30
• 3 Schimmack G, Defronzo RA, Musi N. AMP-activated protein kinase: Role in metabolism and therapeutic implications.  Diabetes Obes Metab. 2006;  8 591-602
• 4 Sajan MP, Bandyopadhyay G, Miura A, Standaert ML, Nimal S, Longnus SL, Van Obberghen E, Hainault I, Foufelle F, Kahn R, Braun U, Leitges M, Farese RV. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK- , ERK- and PDK1-dependent activation of atypical PKC.  Am J Physiol Endocrinol Metab. 2010;  298 E179-E192
• 5 Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.  J Clin Invest. 2010;  120 2355-2369
• 6 Pan QR, Li WH, Wang H, Sun Q, Xiao XH, Brock B, Schmitz O. Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell.  Horm Metab Res. 2009;  41 799-804
• 7 Kato Y, Koide N, Komatsu T, Tumurkhuu G, Dagvadorj J, Kato K, Yokochi T. Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway.  Horm Metab Res. 2010;  42 632-636
• 8 Dardonville C, Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures.  Med Res Rev. 2004;  24 639-661
• 9 Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG. I1-imidazoline receptors. Definition, characterization, distribution, and transmembrane signaling.  Ann NY Acad Sci. 1995;  763 22-42
• 10 Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion.  Ann NY Acad Sci. 1999;  881 217-228
• 11 Lui TN, Tsao CW, Huang SY, Chang CH, Cheng JT. Activation of imidazoline I2B receptors is linked with AMP kinase pathway to increase glucose uptake in cultured C2C12 cells.  Neurosci Lett. 2010;  474 144-147
• 12 Chang CH, Wu HT, Cheng KC, Lin HJ, Cheng JT. Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats.  Neurosci Lett. 2010;  468 297-299
• 13 Tesson F, Prip-Buus C, Lemoine A, Pegorier JP, Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane.  J Biol Chem. 1991;  266 155-160
• 14 Cheng JT, Liu IM, Tzeng TF, Tsai CC, Lai TY. Plasma glucose-lowering effect of beta-endorphin in streptozotocin-induced diabetic rats.  Horm Metab Res. 2002;  34 570-576
• 15 Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats.  Diabetes. 2006;  55 819-825
• 16 Hwang SL, Liu IM, Tzeng TF, Cheng JT. Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats.  Diabetologia. 2005;  48 767-775
• 17 Chang CH, Tsao CW, Huang SY, Cheng JT. Activation of imidazoline I(2B) receptors by guanidine to increase glucose uptake in skeletal muscle of rats.  Neurosci Lett. 2009;  467 147-149
• 18 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action.  J Clin Invest. 2001;  108 1167-1174
• 19 Hsu JH, Wu YC, Liou SS, Liu IM, Huang LW, Cheng JT. Mediation of Endogenous beta-endorphin by Tetrandrine to Lower Plasma Glucose in Streptozotocin-induced Diabetic Rats.  Evid Based Complement Alternat Med. 2004;  1 193-201
• 20 Liu IM, Liou SS, Cheng JT. Mediation of beta-endorphin by myricetin to lower plasma glucose in streptozotocin-induced diabetic rats.  J Ethnopharmacol. 2006;  104 199-206
• 21 Evans A, Smith ME. Effect of beta-endorphin C-terminal peptides on glucose uptake in isolated skeletal muscles of the mouse.  Peptides. 1997;  18 165-167
• 22 Ou HY, Cheng JT, Yu EH, Wu TJ. Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects.  Horm Metab Res. 2006;  38 106-111
• 23 Hsu CT, Liu IM, Cheng JT. Increase of beta-endorphin biosynthesis in the adrenal gland of streptozotocin-induced diabetic rats.  Neurosci Lett. 2002;  318 57-60
• 24 Krug AW, Ehrhart-Bornstein M. Adrenocortical dysfunction in obesity and the metabolic syndrome.  Horm Metab Res. 2008;  40 515-517
• 25 Lachaud-Pettiti V, Podevin RA, Chretien Y, Parini A. Imidazoline-guanidinium and alpha 2-adrenergic binding sites in basolateral membranes from human kidney.  Eur J Pharmacol. 1991;  206 23-31
• 26 Coupry I, Atlas D, Podevin RA, Uzielli I, Parini A. Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance.  J Pharmacol Exp Ther. 1990;  252 293-299
• 27 Joshi MS, Ferguson Jr TB, Johnson FK, Johnson RA, Parthasarathy S, Lancaster Jr JR. Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells.  Proc Natl Acad Sci USA. 2007;  104 9982-9987
• 28 Olmos G, Alemany R, Boronat MA, Garcia-Sevilla JA. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes.  Ann NY Acad Sci. 1999;  881 144-160
• 29 Miralles A, Olmos G, Sastre M, Barturen F, Martin I, Garcia-Sevilla JA. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains.  J Pharmacol Exp Ther. 1993;  264 1187-1197
• 30 Diamant S, Eldar-Geva T, Atlas D. Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function.  Br J Pharmacol. 1992;  106 101-108

Correspondence